Global Regulation of Nanotechnologies and Their Products in Medicine
Nanotechnology, an emerging technology, is creating innovative medicinal products for clinical use. The convergence of nanotechnologies with medicine is predicted to transform the health care sector, particularly pharmaceutical development. Jurisdictions, such as the European Union, the United States, Australia, and New Zealand, have witnessed the launch of medical products containing nanomaterials. Many of the nanomedicines on the market, in clinical testing, or under regulatory review, promise to improve existing products and treat diseases more effectively. The purposes of this chapter are to (a) describe nanotechnology, in particular, its clinical applications; (b) analyze the application of medical products regulation in several jurisdictions (the European Union, United States, Australia, and New Zealand); and (c) assess the adequacy of this law for managing the potential risks posed by nanomedicines. There are gaps in the public health/health science evidence about the risks associated with nanomedicines, and there is concern that the novel properties of some nanomedicines will bring unforeseen human and environmental health and safety risks. Analysts project that, by 2014, the market for medical products containing nanomaterials will be US$18 billion per year. Given the predicted market for nanomedicines, and the growing evidence of their potential risks, it is important to have adequate regulation of these products to prevent adverse public health outcomes. Regulators and clinicians will need to consider the risks posed by some nanomedicines against the potential benefits to patients who are prescribed these products.
Editor: Beran, Roy G
ISBN: 8-3-642-32338-6 (eBook)
Rights Statement: Springer-Verlag Berlin Heidelberg 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein
Keywords: nanotechnology; regulation of nanotechnology; nanomedicine; risk
Research Type: Chapter in Book